奥沙利铂联合吉西他滨治疗晚期非小细胞肺癌的临床疗效

Clincal effects of oxaliplatin in combination with gemcitabine regimen for advanced non-small cell lung cancer

目的观察奥沙利铂(L-OPH)联合吉西他滨(GEM)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应.方法 2002年12月至2004年12月,50例晚期NSCLC患者随机分成治疗组(n=26)与对照组(n=24),治疗组采用L-OPH联合GEM的方案;对照组采用顺铂联合GEM方案.21～28 d为一个周期,完成2个周期后分别观察其近期疗效及不良反应.结果治疗组与对照组有效率分别为38.5%和33.3%.2组不良反应主要是骨髓抑制、胃肠道反应、神经毒性.结论 L-OPH联合GEM治疗晚期NSCLC疗效较好,不良反应轻微,耐受性好.

AIM To evaluate the effects and toxicity of oxaliplatin ＋ gemcitabine regimen for advanced non-small cell cancer（NSCLC）. METHODS From December 2002 to December 2004,50 patients of NSCLC were divided randomly into study group（ n = 26） and control group（ n = 24）. Study group received the regimen of oxaliplatin ＋ gemcitabine, and control group received the regimen of cisplatin ＋ gemcitabine, every 21 - 28 d as one cycle. The response and the chemotherapy toxicity were observed after two cycles for each patient. RESULTS The response rate was 38.5 % （10/26） for study groups regimen and 33.3 % （8/24） for control group regimen, respectively. The major toxicity in the 2 groups were bone marrow suppression, gastrointestinal reaction and neurotoxicity. CONCLUSION The combination of oxaliplatin and gemcitabine is an effective regimen in the treatment of advanced NSCLC.